NCT02716116 2026-02-25A Study of TAK-788 in Adults With Non-Small Cell Lung CancerTakedaPhase 1/2 Active not recruiting334 enrolled 1 FDA
NCT03974022 2026-01-29Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Dizal PharmaceuticalsPhase 1/2 Active not recruiting315 enrolled 37 charts 1 FDA
NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT03157128 2025-10-20LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 3 FDA
NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT01970865 2024-08-12A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular AlterationsPfizerPhase 1/2 Completed364 enrolled 89 charts 1 FDA
NCT01631552 2021-08-12Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerGilead SciencesPhase 1/2 Completed515 enrolled 28 charts 2 FDA